Sabby Management’s Adverum Biotechnologies ADVM Stock Holding History

Sabby Management’s Portfolio ADVM Stock Details ADVM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-223	Closed	-$1.35M	–	122
2018 Q3	$1.35M	Sell	223 -148	-40%	-$8.31K	0.17%	47
2018 Q2	$1.96M	Buy	371 +277	+295%	+$16.7K	0.3%	45
2018 Q1	$548K	Buy	+94	New	+$5.85K	0.07%	93
2016 Q2	–	Sell	-11	Closed	-$55K	–	289
2016 Q1	$55K	Buy	+11	New	+$614	﹤0.01%	279
2015 Q4	–	Sell	-53	Closed	-$437K	–	316
2015 Q3	$437K	Buy	+53	New	+$6.77K	0.02%	305
2015 Q2	–	Sell	-8	Closed	-$328K	–	322
2015 Q1	$328K	Buy	+8	New	+$3.38K	0.01%	249

Other funds holding ADVM

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

WS Management Jacksonville, Florida $1.13B AUM 53.44% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Sabby Management's ADVM Position: Q3 2018 in Review

Sabby Management sold out of Adverum Biotechnologies (ADVM) in Q3 2018, closing a stake of 2,726 shares — an estimated $153K sold.

Sabby Management first reported a position in ADVM in Q3 2014 and held it in 15 quarters. The position peaked at $4.73M in Q3 2015. 101 funds tracked by Wall St. Rank hold ADVM as of Q3 2018.

Sabby Management reported no remaining Adverum Biotechnologies position as of Q3 2018 after selling out during the quarter.
Sabby Management sold 2,726 Adverum Biotechnologies shares in Q3 2018, an estimated $153K.
Sabby Management first reported a position in Adverum Biotechnologies in Q3 2014 and held it in 15 quarters.
Sabby Management's Adverum Biotechnologies position peaked at $4.73M in Q3 2015.
101 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q3 2018.

Based on Sabby Management's 13F filing for Q3 2018, filed 14 Nov 2018.